Around one-third of non-small-cell lung cancers (NSCLCs) are driven by mutations in EGFR. The most common of these alterations (in ~85% of patients) are exon 19 deletions and exon 21 L858R; the remaining alterations are referred to as uncommon. Osimertinib is the standard-of-care first-line therapy for patients with metastatic EGFR-mutated NSCLC, although limited evidence is available on efficacy in those with uncommon mutations. Now, data from the single-arm phase II UNICORN trial reveal that first-line osimertinib has promising activity in this patient population.

中文翻译：

---

具有罕见 EGFR 突变的患者也可从一线奥希替尼中受益

大约三分之一的非小细胞肺癌 (NSCLC) 是由EGFR突变引起的。这些改变中最常见的（约 85% 的患者）是外显子 19 缺失和外显子 21 L858R；其余的改变被认为是不常见的。奥希替尼是转移性EGFR突变 NSCLC患者的标准一线治疗，尽管关于罕见突变患者疗效的证据有限。现在，单臂 II 期 UNICORN 试验的数据表明，一线奥西替尼在该患者群体中具有良好的活性。